DBV Technologies S.A. (DBV.PA)
Develops patch-based treatments for food allergies and immune disorders.
2.37-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+45.3%
The outlook
DBV Technologies trades near multiyear lows, sitting well below its 50- and 200-day moving averages. Analysts lean bullish with an average target implying 60% upside from the current price, though coverage is limited at three firms. The stock remains in the lower portion of its 52-week range, reflecting sustained downward pressure despite the constructive analyst view.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range30% of the way from its 52-week low to high
Price targetAvg target +60% vs current price
Analyst price target
~12-month · 3 analysts3.80average target+60.2% vs now
Now 2.37
Low 1.00High 5.50
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$701.9M
52-wk high
4.50
52-wk low
1.45
50-day avg
2.89
200-day avg
3.18
Trailing P/E
—